Stable Oral Solution for Baclofen, Sorbitol, and Naltrexone

The patent applies parameter changes by systematically adjusting pH levels (testing ranges from pH 3 to pH 8) and buffer concentrations to find optimal conditions that maintain formulation stability. The invention identifies pH 5.0-6.0 as the optimal range where all three APIs remain stable, resolving the contradiction between combining multiple APIs and maintaining formulation stability.

The patent uses buffer systems (citrate buffer, phosphate buffer, acetate buffer) as intermediaries to mediate between the incompatible APIs. These buffers act as protective intermediaries that maintain pH stability and prevent direct interactions between baclofen, sorbitol, and naltrexone that would otherwise cause degradation, enabling their co-administration in a single stable formulation.

The patent changes the pH parameter to a moderate range (pH 5.0-6.0) that is sufficient to maintain baclofen solubility without requiring strong acids or bases. This parameter optimization achieves the necessary solubility enhancement while avoiding the harmful effects associated with extreme pH conditions, thus resolving the contradiction between solubility and safety.

The patent converts the potential harm of pH adjustment into a benefit by using mild buffering agents at physiological pH ranges. Instead of using harmful strong acids or bases, the invention employs food-grade buffers (citrate, phosphate, acetate) that provide the necessary pH environment for solubility while being safe for oral administration, effectively converting a potentially harmful approach into a beneficial one.

The patent applies parameter changes by optimizing the concentration ranges of each API within the formulation. By defining specific concentration parameters (baclofen 0.1-10 mg/mL, sorbitol 10-500 mg/mL, naltrexone 0.01-1 mg/mL) and their ratios, the invention enables accurate manufacturing while maintaining the ability to treat heterogeneous conditions. The standardized parameter ranges facilitate precise manufacturing.

The patent applies the homogeneity principle by ensuring all three APIs are dissolved and uniformly distributed in the liquid formulation matrix. The use of buffer systems and surfactants creates a homogeneous solution where APIs are evenly dispersed at molecular levels, eliminating distribution heterogeneity and enabling precise dosing while maintaining the flexibility to treat varying patient conditions.

The patent uses preservatives (parabens, benzoates, sorbates) as intermediary protective agents that prevent microbial contamination without affecting patient compliance. These preservatives act as intermediaries between the oral liquid formulation and microorganisms, providing a chemical barrier that maintains formulation integrity while allowing the convenient liquid form to be used for chronic treatment.

The patent applies parameter changes by optimizing pH to the range of 5.0-6.0, which creates an environment less favorable for microbial growth while still maintaining API stability and solubility. This pH optimization, combined with the use of preservatives, reduces microbial contamination risk while preserving the advantages of oral liquid formulation for improving patient compliance in chronic treatment.